Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-21-018110
Filing Date
2021-05-04
Accepted
2021-05-04 16:30:25
Documents
1
Period of Report
2021-04-30

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4057
  Complete submission text file 0000899243-21-018110.txt   5478
Mailing Address C/O SYNDAX PHARMACEUTICALS, INC. 400 TOTTEN POND ROAD, SUITE 110 WALTHAM MA 02451
Business Address
Morrison Briggs (Reporting) CIK: 0001654430 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40366 | Film No.: 21888987

Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138 617-952-0555
Werewolf Therapeutics, Inc. (Issuer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations